[HTML][HTML] Sequence of treatment in locally advanced and metastatic renal cell carcinoma
S Fischer, S Gillessen… - … andrology and urology, 2015 - ncbi.nlm.nih.gov
The spectrum of drugs that have shown activity in advanced or metastatic renal cell
carcinoma (RCC) has led to a debate on the optimal sequence of treatments. There is …
carcinoma (RCC) has led to a debate on the optimal sequence of treatments. There is …
Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
JML Ebos, M Mastri, CR Lee, A Tracz… - EMBO molecular …, 2014 - embopress.org
Thousands of cancer patients are currently in clinical trials evaluating antiangiogenic
therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to …
therapy in the neoadjuvant setting, which is the treatment of localized primary tumors prior to …
[HTML][HTML] Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma—Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study
S Oudard, L Geoffrois, A Guillot, C Chevreau… - European Journal of …, 2016 - Elsevier
Aim To assess the efficacy and tolerability of sunitinib rechallenge in the third-line or later
setting in patients with metastatic renal cell carcinoma (mRCC). Patients and methods This …
setting in patients with metastatic renal cell carcinoma (mRCC). Patients and methods This …
Improving outcomes in metastatic clear cell renal cell carcinoma by sequencing therapy
M Schmidinger - American Society of Clinical Oncology Educational …, 2014 - ascopubs.org
Targeted agents have substantially improved outcomes in metastatic clear cell renal cell
carcinoma. However, due to multiple mechanisms of evasive resistance, almost all patients …
carcinoma. However, due to multiple mechanisms of evasive resistance, almost all patients …
[PDF][PDF] Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity
GM Cofino - 2014 - savoirs.usherbrooke.ca
Sunitinib (Sutent®) is a multitargeted, small molecule receptor tyrosine kinase inhibitor used
as an anti-cancer drug. It has increased the overall survival rate of metastatic renal cell …
as an anti-cancer drug. It has increased the overall survival rate of metastatic renal cell …
Positron Emission Tomography (PET) for the early detection of sunitinib-induced cardiotoxicity.
G Marrero Cofino - 2014 - library-archives.canada.ca
Abstract Abstract: Sunitinib (Sutent®) is a multitargeted, small molecule receptor tyrosine
kinase inhibitor used as an anti-cancer drug. It has increased the overall survival rate of …
kinase inhibitor used as an anti-cancer drug. It has increased the overall survival rate of …